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ABSTRACT
Purpose To assess the effect of ranibizumab treatment
for neovascular age-related macular degeneration
(nvAMD) on patients’ preferences and vision-related
quality of life (VRQoL) in a routine clinical setting.
Methods 55 treatment naı̈ve patients were examined
before and after the initial upload of three monthly
injections of 0.5 mg ranibizumab. VRQoL was assessed
using a Rasch-adjusted NEI-VFQ-25. Time trade-off
(TTO), standard gamble, a visual analogue scale and the
European Quality of Life Questionnaire (EQ-5D) were
used to calculate utilities, and multiple logistic regression
models were conducted to determine independent
factors associated with utilities.
Results Mean6SD age was 7567 years, and 40
patients (73%) were female. Mean6SD best-corrected
visual acuity of the treated eye increased from 20/80 at
baseline (logMAR 0.6060.35) to 20/63 (logMAR
0.5260.36; p¼0.020) at follow-up after three injections.
Utility score increases ranged from 2 utils (standard
gamble anchored for death) up to 6.6 utils (EQ-5D
German TTO, p¼0.023) and visual functioning improved
(Rasch adjusted composite NEI-VFQ score 50621 to
54621, p¼0.042). Whether the worse or better eye
was treated was not significantly associated with
improvements in utility or VRQoL, whereas VA
improvement in the treated eye was associated with an
increase in utility (TTO, p¼0.020).
Conclusions TTO performed best in this sample of
elderly nvAMD patients undergoing anti-VEGF therapy.
Better or worse eye treatment was not associated with
a change in reported utilities or visual functioning in
patients with newly diagnosed nvAMD. Directly elicited,
vision-specific utilities gained with TTO seem to be
sensitive to a change in vision status.
INTRODUCTION
A positive effect of ranibizumab treatment on
patients’ vision related quality of life (VRQoL) in
neovascular (nv) age-related macular degeneration
(AMD) has been reported in several studies.1 2 One
way to assess the impact of treatment on patients’
QoL and, in particular, the satisfaction derived from
a specific health outcome, is to assess utilities.
Utility in a general sense refers to the preference an
individual or society may have for any particular
set of health outcomes. Utilities are a crucial
measure for costebenefit analyses and are used
widely by policy planners for allocation of health-
care resources.3 Commonly used tools to determine
utilities in ophthalmology include the time trade-
off method (TTO), standard gamble (SG) and the
European Quality of Life Questionnaire (EQ-5D).4
The different approaches have different limitations.
TTO and SG are affected by time and duration
effects, and SG by attitudes to risk as well as
anchoring issues, while generic health-related QoL
utilities, especially the EQ-5D, may not be sensitive
to the specific effects of vision or vision impairment
since they often do not contain vision-related
content. Utility values and remaining life years are
then used to calculate quality adjusted life years
(QALYs), which are the basis of economic evalua-
tions in healthcare.
When considering healthcare resource allocation
for treatment of nvAMD, economic evaluations
frequently differentiate between treatment of the
first (worse) and second (better) eye, assuming
a differential impact on patients’ preferences (util-
ities) and QoL, and thus differing cost implications
and costebenefit ratios.5 However, no data on
patient reported preferences for anti-VEGF treat-
ment of nvAMD assessed by standard utility
instruments are currently available. Therefore, we
investigated the effect of ranibizumab treatment
for nvAMD on patients’ preferences and VRQoL in
a routine clinical setting using a range of utility
methods, assessing their performance and appro-
priateness.
PATIENTS AND METHODS
Patients were recruited from the outpatient clinic
at the Department of Ophthalmology, University
of Munich, between September 2009 and March
2010. Approval was obtained from the Institutional
Review Board of the University of Munich. All
patients gave signed informed consent for study
participation before enrolment and start of treat-
ment. The study adhered to the tenets of the
Declaration of Helsinki.
Patients and intervention
Only treatment naïve, newly diagnosed patients
with nvAMD were included. The diagnosis of
nvAMD was confirmed by fluorescein angiography.
Patients received three monthly intravitreal injec-
tions of 0.5 mg ranibizumab. Participants under-
went a full ophthalmological examination pre- and
post-treatment, including best-corrected visual
acuity (BCVA) using retro-illuminated logMAR
ETDRS charts (Lighthouse International, New
York, USA), fundus photography and optical
coherence tomography. VRQoL and patients’ pref-
erences were recorded at baseline and follow-up
after the third ranibizumab injection, in order to
ensure that all patients underwent the same
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treatment regime and that the treatment effect was likely to be
at its maximum level possible.
Vision-related quality of life
The National Eye Institute Visual Function Questionnaire 25
Item (NEI-VFQ-25), a well evaluated tool available in German,6
is one of the most widely used QoL scales in ophthalmology. In
the current study, we performed Rasch analysis to assess the
measurement properties of the German NEI-VFQ-25.
Psychometric validation of the German NEI-VFQ-25
In brief, Rasch analysis is a modern psychometric method that
mathematically describes the interaction between respondents
and test items. The Rasch model states that the probability of
a correct response is a logistic function of the difference between
person ability (person measure) and item difficulty (item
measure), and applies a strict model which the pattern of
participants’ responses should satisfy. Raw ordinal scores are thus
transformed into data that approximate interval-level measure-
ment (expressed in log of the odds units, or logits). The specific
methodology employed has been described in detail elsewhere.7
We performed Rasch analysis using Winsteps software (V.3.68;
Chicago, Illinois, USA).
Patient-reported preferences
Health state utilities depend on the individuals’ relative prefer-
ences for different health states. The instruments used to assess
the patients’ preferences in this study included TTO, SG and the
Euro-QoL (EQ-5D).4
Time trade-off
Within the TTO utility assessment, the respondents are asked to
trade-off life for gains in health status. In ophthalmology the
perfect health state is set at full visual function. The utility
value is calculated as a ratio of the highest state of QoL equalling
a utility value of 1.0, whereas the worst utility value is 0.8
TTO was conducted as follows. The first question to
respondents was “How many years do you still expect to live?”,
followed by the second question “Assuming that there was
a technology which restores you to full vision, what is the
maximum number of remaining years of life you would be
willing to give up if you could receive this technology and have
normal vision in both eyes for the rest of your life?” Utilities
were calculated as: (expected life years  years willing to trade
off)/expected life years.
Standard gamble
A typical SG lottery asks a person to choose between experi-
encing a specific health state with certainty for the rest of their
life and a lottery, usually described as a medical intervention,
with two possible outcomes: an immediate return to perfect
health with probability p or immediate death with probability
(1p). The probabilities of the two outcomes are repeatedly
adjusted until the person indicates equal preferences between
the certain health state and the lottery. The utility weight for
the certain health state is equal to the individually adjusted
probability p.
In our study, we performed two SG approaches which were
anchored for two worst lottery outcome health states: death
and blindness. Two anchor points were chosen as the readiness
to take risks depends on the worst outcome.9 The SG utilities
were estimated using a computer-based preference assessment
interview platform (X-trade).
EQ-5D and visual analogue scale
The EQ-5D is a generic multi-attribute utility instrument
developed by the EuroQoL group,10 comprising five dimen-
sionsdmobility, self-care, usual activities, pain/discomfort and
anxiety/depressiondand three severity levels. The EQ-5D also
includes a visual analogue scale (VAS), which comprises a line
with numbers between 0 (worst health-state) and 100 (best
health-state). The raw data of the EQ-5D values were converted
into utilities using the suggested conversion algorithms
anchored for the VAS for a European (European VAS) and
German (German VAS) collective and by TTO for a German
collective (German TTO).
Statistical analyses
SPSS V.19.0 was used to analyse the data. Descriptive statistical
analyses were performed to characterise the participants’ soci-
odemographic, clinical, utility and VRQoL data, stratified by
better or worse eye treated. Correlational analyses (bivariate and
intraclass) were used to explore employed utility measures.
Instruments were grouped into directly elicited, vision-specific
utilities (TTO and SG, including different anchors), general
utilities (different weights for the EQ-5D) and VRQoL estimates
(VAS and Rasch scored NEI-VFQ-25). Fully-adjusted logistic
regression models were conducted to determine the independent
factors associated with patient-reported preferences (utilities)
and VRQoL. Visual acuity was categorised into two categories:
normal presenting vision in the better eye (<0.4 logMAR); and
visual impairment and blindness (logMAR $0.4). All tests were




A total of 55 patients with newly diagnosed and treatment naïve
nvAMD participated in the study (table 1). Mean6SD age was
7567 years, and 40 patients (73%) were female. The mean
BCVA of the treated eye increased from 20/80 at baseline
(logMAR 0.6060.35) to 20/63 (logMAR 0.5260.36; p¼0.020) at
follow-up after three injections (table 1). Mean BCVA of the
fellow eye was 20/63 (logMAR 0.4660.64) and did not change
during the study period. VA significantly improved only in
treated worse eyes (logMAR 0.6960.35 to 0.5760.38; p¼0.013).
Visual acuity in treated better seeing eyes remained stable
(logMAR 0.4360.31).
Utility scores increased for the whole sample pre- and post-
treatment from 2 utils (SG anchored for death) up to 6.6 utils
(EQ-5D German TTO). The only statistically significant utility
value increase for the whole sample was found with the EQ-5D
German TTO utilities and the VAS measurement (p¼0.023 and
p¼0.001, respectively, table 1). There was no measurable change
in utility scores over time within or between the worst or better
eye treatment groups except for the VAS measurement which
improved in patients whose worse eye was treated (p#0.01;
table 1).
Psychometric evaluation of the NEI-VFQ
After a number of revisions of the original scale, including
collapsing response categories to three and splitting the multi-
dimensional overall scale into two scales, a visual functioning
and socioemotional well-being subscale, the visual functioning
subscale of the NEI-VFQ-25, demonstrated good measurement
characteristics as shown in table 2. Discriminant ability of the
socioemotional scale could not be improved by further deletion
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or inclusion of items. Thus the socioemotional scale was only
used in the correlational analyses (table 3) but not in any of the
regression models. The process is outlined in a previous Rasch
analysis of the NEI-VFQ-25.11 To facilitate the interpretation of
the person measure scores, they were recalibrated from a nega-
tiveepositive logit scale to range between 0 and 100 following
Rasch analysis. Visual functioning improved from baseline to
follow-up in the whole sample by 4.0 points on the transformed
VFQ scale (50621 to 54621, p¼0.042; table 1). As with the
utility measures, no differences were found for visual func-
tioning over time within or between the better and worse eye
treatment groups.
Table 1 Characteristics of the sample (n¼55)
Total sample Worse eye treated Better eye treated
p Valuexn[55 n[36 n[18
Proportion
Gender
Male 15 (27.3%) 12 (33.3%) 3 (16.7%) 0.197y
Female 40 (72.7%) 24 (66.7%) 15 (83.3%)
Age (years), mean6SD 75.566.9 75.667.0 75.267.0 0.837z
Total sample Worse eye treated Better eye treated
p Valuexn[55 n[36 n[18
BL FU BL FU BL FU BLz FUz
Treated eye VA (logMAR)
Mean6SD 0.6060.35 0.5260.36 0.6960.35 0.5760.38 0.4360.31 0.4360.32
p Value* 0.020 0.013 0.987 0.011 0.194
Other eye VA (logMAR)
Mean6SD 0.4660.64 0.4760.61 0.1960.15 0.2260.20 1.0160.86 0.9660.83
p Value* 0.630 0.044 0.280 0.001 0.002
Better eye VA (logMAR)
Mean6SD 0.2760.24 0.2960.26 0.1960.15 0.2260.19 0.4360.31 0.4260.32
p Value* 0.469 0.239 0.604 0.004 0.006
Standard gamble death
Mean6SD 0.9560.12 0.9760.08 0.9560.13 0.9860.05 0.9460.10 0.9660.12
p Value* 0.364 0.352 0.782 0.858 0.511
Standard gamble blindness
Mean6SD 0.9560.12 0.9860.06 0.9560.12 0.9860.05 0.9560.10 0.9860.08
p Value* 0.135 0.231 0.384 0.981 0.979
TTO
Mean6SD 0.8960.16 0.9260.16 0.8760.16 0.9060.17 0.9560.03 0.9560.04
p Value* 0.326 0.368 0.904 0.074 0.373
EQ-5D German TTO
Mean6SD 0.7960.26 0.8660.20 0.8060.27 0.8760.20 0.7860.25 0.8360.22
p Value* 0.023 0.067 0.245 0.763 0.534
Visual analogue scale
Mean6SD 53.27614.43 61.36618.0 53.06613.99 65.14616.50 52.7863.67 52.5064.24
p Value* 0.001 <0.001 0.945 0.947 0.018
NEI-VFQ visual functioning
Mean6SD 50621 54621 51619 56618 44624 48624
p Value* 0.042 0.086 0.390 0.286 0.177
Emboldened values indicate statistical significance.
*Two-tailed paired t-test.
yPearson’s c2.
zIndependent samples two-tailed t-test.
xp Value refers to the difference in baseline and follow-up scores between the worse and better eye treatment groups.
EQ-5D, European Quality of Life Instrument, 5 dimensions; NEI-VFQ, National Eye Institute Visual Functioning Questionnaire; TTO, time trade-off; VA, visual acuity; VAS, visual analogue scale.




NEI-VFQ-25 Rasch guided subscales
Visual functioning Socioemotional
Item no. 1e25 5e14 3, 17, 18, 20e24
Number of misfitting items 0 9 0 0
Person separation >2.0 2.16 2.21 1.58
Person reliability >0.8 0.82 0.83 0.71
Person mean 0 1.13 1.47 2.69
Principal components analysis
(eigenvalue for first contrast)
<2.0 3.8 1.6 1.8
Variance by the first factor >50% 49.6% 53.5% 68.1%
Br J Ophthalmol 2012;96:997e1002. doi:10.1136/bjophthalmol-2011-301201 999
Clinical science
The relation of reported utilities
All vision-specific utilities, namely the SG anchored for death
and blindness and the TTO, were highly correlated using Pear-
son’s correlation coefficient (table 3) and intraclass correlation
(r>0.5; p<0.001 for all). All three measures showed similar
ceiling effects, but only SG measures were correlated to VA, VAS
and person measures (visual functioning and socioemotional
well-being, table 3). As the SG anchor for blindness cannot be
used to calculate QALYs, we only used the SG anchored for
death for subsequent analyses.
The three different weightings for the EQ-5D data were
highly correlated with each other; however, they correlated to
no other clinical measures. Ceiling effects were present but less
marked than for SG and TTO. In subsequent analyses, only the
German TTO weighting was used.
The Rasch guided person measures for the visual functioning
and socioemotional well-being subscales of the NEI-VFQ-25 and
the EQ-5D based VAS rating were all inter-correlated and
correlated to both SG ratings, but were not correlated with other
clinical measures (table 3).
The impact of treatment on patients’ preferences
We created binary variables for all utility scores at follow-up,
categorising the change into improvement (including stable
scores, difference to baseline $0) and worsening (difference to
baseline <0). Logistic regression models were used to examine the
association between an improvement in patient reported prefer-
ences and ranibizumab treatment for nvAMD. An improvement
of vision in the treated eye was significantly associated with an
improvement in the TTO score (p¼0.020; table 4). However,
whether the better or worse eye was treated was not significantly
associated with any of the utility measures. Age was significantly
associated with reported differences in SG anchored for death
(p¼0.010) and the EQ-5D German TTO (p¼0.038; table 4). An
improvement in visual functioning as measured with the NEI-
VFQ-25 subscale was significantly associated with an improve-
ment in reported scores for SG anchored for death (p¼0.025).
DISCUSSION
In this sample, ranibizumab treatment for nvAMD led to an
improvement in visual acuity of the treated eye, patient reported
visual functioning and utilities as measured with TTO and the
EQ-5D anchored for German TTO. In multivariate analyses,
better or worse eye treatment was not significantly associated
with any utility measures, whereas an improvement of vision in
the treated eye was significantly associated with increased TTO
utilities. SG utilities (both anchors) were highly concordant but
were not responsive to treatment in this sample. This has
important implications for economic evaluations of ophthalmic
interventions as it suggests that vision-specific, directly elicited
utilities collected with TTO may be most sensitive to a change
in vision status. Generally, responsiveness of utility instruments
to change over time, that is after an intervention, remains
a challenge to be addressed.
Table 3 Correlations of utility measures and visual acuity at baseline (bivariate Pearson’s correlation coefficients)
ETDRS letters SG death SG blindness TTO
EQ-5D
European VAS EQ-5D German TTO EQ-5D German VAS VAS PM VF PM SEW
ETDRS letters baseline
CC 1 0.288* 0.295* 0.046 0.092 0.042 0.120 0.091 0.065 0.066
p 0.045 0.039 0.748 0.521 0.771 0.402 0.526 0.651 0.648
SG death
CC 1 0.825y 0.312* 0.099 0.046 0.102 0.360y 0.471y 0.446y
p 0.000 0.023 0.482 0.741 0.469 0.008 0.000 0.001
SG blindness
CC 1 0.466y 0.160 0.081 0.134 0.349* 0.341* 0.343*
p 0.000 0.252 0.563 0.340 0.010 0.013 0.012
TTO
CC 1 0.074 0.024 0.047 0.048 0.031 0.031
p 0.593 0.862 0.731 0.728 0.823 0.821
EQ-5D European VAS
CC 1 0.927y 0.975y 0.196 0.177 0.083
p 0.000 0.000 0.153 0.197 0.546
EQ-5D German TTO
CC 1 0.934y 0.226 0.081 0.048
p 0.000 0.097 0.558 0.728
EQ-5D German VAS
CC 1 0.217 0.181 0.113
p 0.111 0.186 0.410
VAS








*Correlation is significant at the 0.05 level (2-tailed).
yCorrelation is significant at the 0.01 level (2-tailed).
CC, correlation coefficient; SG, standard gamble; TTO, time trade-off; VAS, visual analogue scale; VF, visual function.
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Use of utility instruments comes with a range of inherent
challenges. Whether utility measures are sensitive to changes in
health status over a short period of time is debatable.12 Similarly,
anchoring them for perfect visiondblindness rather than perfect
health or deathdis controversial9 as utility measures tend to
produce lower utilities when anchored for blindness rather than
death, which makes comparability across different illnesses and
interventions difficult.9 Indeed, SG anchored for blindness was
not associated with any of the assessed factors in our study.
This, coupled with the high concordance of both measures,
suggests that anchoring for death is appropriate as this yields
universally comparable results. Another issue concerns obtaining
utilities from an elderly sample with a short remaining life span
and low willingness to trade any of it for an intervention. This is
reflected in our study where most utility values were associated
with age. The VAS, as a magnitude estimate of health, or in this
case VRQoL, was highly correlated to the NEI-VFQ-25 person
measures, but not with other utility measures. Thus we would
not recommend it to be used as the sole utility measure in any
research scenario.
Better or worse eye treatment was not associated with
improvements in utilities in our study. This may have implica-
tions for cost-effectiveness analyses which often assume
a differential impact of better or worse eye treatment on utili-
ties. Utility values used for economic evaluation in ophthal-
mology, in particular in the field of AMD, are often deduced
using approximations from clinical data (eg, visual acuity) rather
than from directly collected utilities.13 Utilities directly derived
from patients are very likely to differ from utility values inferred
from visual acuity, as patients’ preferences are vastly different
even at the same level of visual acuity.
Vision functioning improved in our sample by four points,
which is similar to the minimal clinically important difference
for the non-Rasch adjusted NEI-VFQ-25 (3e4 points in the
composite score).14 The observed increase in visual functioning
was similar regardless of whether the better or worse eye was
treated, which corresponds to findings reported from the
ANCHOR and MARINA studies.2
Strengths of our study include the use of a standard VRQoL
instrument and a large array of utility tools to assess ranibi-
zumab treatment effects in nvAMD, which has not been
performed previously. Moreover, the use of three different
population value sets to calculate the EQ-5D utilities is also
important, especially given the varying findings in our study.
Further strengths include the use of Rasch analysis to assess the
psychometric properties of the German NEI-VFQ-25, and to
produce interval-level measurements of visual functioning.
Such a psychometric evaluation has not been done for the
German version of the NEI-VFQ-25 to date. Our study setting
in daily clinical routine better reflects actual treatment condi-
tions and outcomes than highly standardised phase III clinical
trials. The main limitation of our study is the small sample size,
and uneven size of the subgroups for better and worse eye
treatment, which may have diminished our ability to reveal
significant associations and ensure that the associations we did
find were not due to chance alone. Indeed, the wide CIs present
for some of our data imply poor precision, and future trials are
required to replicate the findings in a larger sample population.
Another limitation is the short follow-up time; however,
empirical evidence suggests that the largest treatment effect, if
any, is to be expected at 3 months, and then either maintained
or lost over the subsequent months. Indeed, other large rand-
omised studies have shown similar increases in NEI-VFQ-25
visual functioning score at 3 months to that found in our
study.1 2
In conclusion, ranibizumab treatment for nvAMD leads to
improvements in visual acuity, patient reported visual func-
tioning and patient preferences, as elicited by TTO. Non
vision-specific utility measures, or SG anchored for blindness,
did not detect a change over time. Better or worse eye treat-
ment was not associated with any of the patient reported
utilities assessed, suggesting that gain in utility from better
and worse eye treatment may be similar and that differential
allocation of resources in cost-effectiveness analyses may not
be warranted.
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